Astellas Pharma EBITDA 2012-2024 | ALPMY

Astellas Pharma EBITDA for the quarter ending June 30, 2024 was $0.646B, a 11.88% decline year-over-year.

  • Astellas Pharma 2024 EBITDA was 1.215B, a 32.31% decline from 2023.
  • Astellas Pharma 2023 EBITDA was 1.795B, a 6.95% decline from 2022.
  • Astellas Pharma 2022 EBITDA was 1.929B, a 2.55% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Astellas Pharma EBITDA 2012-2024 | ALPMY

  • Astellas Pharma 2024 EBITDA was 1.215B, a 32.31% decline from 2023.
  • Astellas Pharma 2023 EBITDA was 1.795B, a 6.95% decline from 2022.
  • Astellas Pharma 2022 EBITDA was 1.929B, a 2.55% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$76.9B
Takeda Pharmaceutical (TAK)$43.9B
Merck (MKKGY)$20.8B
Sandoz Group AG (SDZNY)$19.6B
United Therapeutics (UTHR)$17.7B
Summit Therapeutics (SMMT)$15.4B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.9B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$5.7B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.7B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$3B
Catalyst Pharmaceuticals (CPRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Ardelyx (ARDX)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B